Skip to content
Axcess News – Lifestyle
Author:
Palvella Therapeutics Inc.
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
March 6, 2026
Palvella Therapeutics Announces Pricing of Upsized Public Offering
March 6, 2026
Palvella Therapeutics Announces Proposed Public Offering
March 5, 2026
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
March 5, 2026
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
March 5, 2026
←
Previous Page
1
2
3